(4-fluoro-3-methoxyphenyl)-[5-(4-fluorophenoxy)pyridin-2yl]amine | 1139717-32-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (4-fluoro-3-methoxyphenyl)-[5-(4-fluorophenoxy)pyridin-2yl]amine
• 英文别名: N-(4-fluoro-3-methoxyphenyl)-5-(4-fluorophenoxy)pyridin-2-amine
• CAS: 1139717-32-0
• 化学式: C₁₈H₁₄F₂N₂O₂
• 分子量: 328.318
• InChiKey: PTGIQWPWAUWMDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  43.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-chloro-5-(4-fluorophenoxy)pyridine 、 4-氟-3-甲氧基苯胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 48.0h， 以23%的产率得到(4-fluoro-3-methoxyphenyl)-[5-(4-fluorophenoxy)pyridin-2yl]amine
  参考文献：
  名称：

  PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES

  摘要：

  该化合物的结构式（I）或其药用可接受的盐或前药：其中X和Y分别独立为NR5或O；W和Z分别独立为键或（CH2）mCH(R7)(CH2)n；m=0-1，n=0-2；R为氢或卤素；R1和R2分别选自氢卤素，CF3，CN，OR8，NR9R10，NR9COR11，NR9SO2R11或C1-6烷基，可选择地被羟基，C1-6烷氧基或NR9R10取代；R3为氢，卤素，CF3，CN，OR8，SR8或SO2R11；R4为氢，卤素，CF3，OR9，NR9R10，NR9COR11，NR9SO2R11或C1-6烷基，可选择地被羟基，C1-6烷氧基或NR9R10取代；R5为氢或C1-6烷基，可选择地被羟基，C1-6烷氧基或NR9R10取代；R6为氢，氟，C1-6烷基或C1-6烷氧基；R7为氢，C1-6烷基，苯基或C1-3烷基苯基，其中所述苯基可选择地被一个或多个取代基取代，所述取代基选自卤素，C1-6烷基，CF3，OCF3或OR9；R8为氢或C1-6烷基，可选择地被氟，C1-6烷氧基或NR9R10取代；R9为氢，C1-6烷基或C1-3烷基苯基，其中所述苯基可选择地被一个或多个取代基取代，所述取代基选自卤素，C1-6烷基，CF3，OR8，NR9R10或OCF3；R10为氢，C1-6烷基，C1-6烯基，苯基或C1-3烷基苯基，其中所述苯基可选择地被一个或多个取代基取代，所述取代基选自卤素，C1-6烷基，CF3，OR8或OCF3；或当连接到氮原子时，R9和R10组合可形成一个可选择地含有来自NR9，S和O的进一步杂原子的5-或6-成员环；R11为C1-6烷基或一个苯基，可选择地被一个或多个取代基取代，所述取代基选自卤素，C1-6烷基，CF3，OCF3或OR8。这些化合物在治疗与淀粉样蛋白相关的疾病中很有用。

  公开号：

  US20100298325A1

文献信息

• [EN] PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES<br/>[FR] DÉRIVÉS DE PYRIDINE POUR LE TRAITEMENT DE MALADIES SE RAPPORTANT AUX AMYLOÏDES
  申请人：SENEXIS LTD

  公开号：WO2009044160A1

  公开（公告）日：2009-04-09

  a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X and Y are independently NR5 or O; W and Z are independently a bond or (CH2)mCH(R7)(CH2)n; m = 0-1, n = 0-2; R is hydrogen or halogen; R1 and R2 are independently selected from hydrogen, halogen, CF3, CN, OR8, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R3 is hydrogen, halogen, CF3, CN, OR8, SR8 or SO2R 11.; R4 is hydrogen, halogen, CF3, OR9, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10;R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R7 is hydrogen, C1-6 alkyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR9; R8 is hydrogen or C1-6 alkyl optionally substituted by fluorine, C1-6 alkoxy or NR9R10; R9 is hydrogen, C1-6 alkyl or C1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8, NR9R10Or OCF3; R10 is hydrogen, C1-6 alkyl, C1-6 alkenyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OR8 or OCF3; or the groups R9 and R10 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR9, S and O; and R11 is C1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR8 is provided. The compounds are useful in treating amyloid related diseases.